The Adenosine A1 Receptor in Breast Cancer: Emerging Target for Therapeutic Intervention

The Adenosine A1 Receptor (A1R), a G-protein-coupled receptor, is gaining recognition as a significant therapeutic target in breast cancer. Its role is particularly prominent in hormone-responsive breast cancers due to a critical feed-forward loop with estrogen receptor-alpha (ERα). In ERα-positive cells, estradiol upregulates A1R expression, and A1R signaling is, in turn, necessary for the full transcriptional activity of ERα, creating a synergistic mechanism that drives cancer cell proliferation. In the hypoxic tumor microenvironment, where extracellular adenosine is abundant due to the enzymatic activity of CD39 and CD73, A1R activation confers a survival advantage by inhibiting apoptosis. This is achieved through downstream signaling that suppresses the tumor suppressor p53 and executioner caspases. This comprehensive investigation outlines an integrated research framework for studying A1R, beginning with in silico methods like target screening with SwissTargetPrediction, pharmacophore modeling, and molecular docking simulations using the A1R crystal structure (PDB ID: 7LD3). These computational predictions are validated through in vitro experiments, such as cell viability (MTT) and apoptosis (Annexin V/PI) assays in breast cancer cell lines like MCF-7. Pharmacological studies using the selective A1R antagonist DPCPX have consistently demonstrated potent anti-proliferative and pro-apoptotic effects, with some rationally designed compounds showing superior efficacy to standard chemotherapeutics like 5-FU. A major challenge in A1R drug development is achieving subtype selectivity over A2A and A2B receptors and mitigating on-target side effects. To address this, advanced strategies such as the development of allosteric modulators and biased agonists are being pursued to fine-tune A1R activity, offering a promising future for targeted breast cancer therapy. Source: https://www.cancerchem.com/posts/the-adenosine-a1-receptor-in-breast-cancer-emerging-target-for-therapeutic-intervention